1

Electrochemical-biosensor Microchip Based on Gold Nanoparticles as a Point-of-Care Test (POCT) for Quantitative Determination of Glycated Hemoglobin (HbA1c)

Kanyarat Boonprasert¹, Thipaporn Tharavanij², Chiravoot Pechyen³, Khanittha Ponsanti⁴, Benchamaporn Tangnorawich⁴, Vithoon Viyanant¹, Kesara Na-Bangchang^{1*}

¹Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand
²Department of Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
³Department of Materials and Textile Technology, Faculty of Science and Technology, Thammasat University, Pathum Thani, Thailand
⁴Department of Physics, Faculty of Science and Technology, Thammasat University, Pathum Thani, Thailand

* **Correspondence:** Kesara Na-Bangchang Email address: kesaratmu@yahoo.com

Keywords: biosensor, diabetes, diagnosis, HbA1c, point-of-care test

Abbreviations: (HbA1c) Glycated hemoglobin, (POCT) Point-of-Care Test, (DM) Diabetes mellitus, (POCT-HbA1c^{MWCNTs/AuNPs}) Nanoparticle-based electrochemical biosensor – multiwalled nanotubes corporated with gold nanoparticles

Word counts: for abstract: 182; for the text: 3,178 Total number of pages: 13 Total number of figures: 5 Total number of tables: 2

Abstract 1

2	Monitoring the level of glycated hemoglobin (HbA1c) has become the gold
3	standard measure of diabetes mellitus diagnosis and control in conjunction with
4	FBG and oral glucose tolerance test. The study aimed to investigate the
5	applicability of the newly developed nanoparticle-based electrochemical
6	biosensor - multiwalled nanotubes corporated with gold nanoparticles (POCT-
7	HbA1cMWCNTs/AuNPs) as a routine POCT for detection of HbA1c for the
8	diagnosis of diabetes mellitus (DM). Finger-prick and venous blood samples were
9	collected 108 DM and 98 non-DM subjects for determination of HbA1c and total
10	hemoglobin by POCT-HbA1cMWCNTs/AuNPs in comparison with standard
11	HPLC method. The performance of the POCT-HbA1cMWCNTs/AuNPs was
12	evaluated using the standard cut-off HbA1c level of >6.5%. The sensitivity,
13	specificity, positive predictive value, and negative predictive value of the test
14	were 100.00%, 90.32%, 87.23%, and 100.00%, respectively. The probability of
15	DM diagnosis in a subject with HbA1c >6.5 (positive predictive value) was
16	87.23% (82/94). The accuracy of the POCT-HbA1cMWCNTs/AuNPs was
17	94.18%, with %DMV (deviation of the mean value) of 0.25%. The results
18	indicate satisfactory assay performance and applicability of the POCT-
19	HbA1cMWCNTs/AuNPs for diagnosis of DM using the cut-off criteria of HbA1c
20	>6.5.
21	

23 Introduction

24	Diabetes mellitus (DM) is a chronic metabolic disorder categorized by
25	elevated levels of plasma glucose due to defects in insulin secretion (type I),
26	insulin action (type II), or both. A series of metabolic diseases follows, which
27	may lead to permanent and irreparable damage, including amputation,
28	retinopathy, neuropathy, and cardiovascular diseases [1]. The growing prevalence
29	of DM is a global concern. Approximately 541 million people are at increased
30	risk for developing type 2 DM. About half of the patients are unaware of their
31	state of illness, and this may lead to delay in proper diagnosis and management
32	[2]. While there is no definitive remedy for DM, disease progression and
33	complications could be minimized by rapid diagnosis and closely monitoring their
34	blood glucose levels [3]. However, fasting plasma glucose concentrations only
35	provide a snapshot of blood glucose at one point in time of blood sample
36	collection and do not provide a long-term vision for disease management [4]. In
37	addition, the level is affected by many different factors and it is not the most
38	effective biomarker for DM diagnosis and control [5]. Monitoring the level of
39	glycated hemoglobin (HbA1c) has become the gold standard measure of DM
40	diagnosis and control in conjunction with FBG and oral glucose tolerance test [6].
41	HbA1c is hemoglobin HbA glucose, which is a typical glycosylated protein in the
42	body that has nonenzymatic covalent attachment of glucose to the N-terminal
43	valine of the beta-globin chain [7]. Its concentration depends on the erythrocyte
44	lifespan and the blood glucose level. The term HbA1c refers to the ratio of HbA1c
45	to total hemoglobin (Hb) concentration, and the normal range of HbA1c is 5 to

46	20% of total Hb. The cut-off value of HbA1c \geq 6.5% is recommended for the
47	diagnosis of DM according to American Diabetes Association and World Health
48	Organization guidelines [8]. Pre-DM is defined as HbA1c of 5.7-6.4%, and non-
49	DM is defined as HbA1c of 4.0-5.6% [9, 10]. Furthermore, HbA1c is also a useful
50	biomarker of long-term glycemia and a good predictor of lipid profile. Monitoring
51	glycemic control could, thus, benefits DM patients with the risk of cardiovascular
52	disease [11]. Accurate and precise methods for HbA1c measurement are therefore
53	required for better glycemic control.
54	Currently, there are various methods available for measurement of HbA1c
55	levels in the blood [12]. These methods are based on separation according to ionic
56	charge (ion-exchange chromatography, electrophoresis) [13, 14], affinity binding
57	(affinity chromatography for HbA1c) [15], enzymatic assays [16], colorimetric
58	assays [17], or immunoassays [18, 19]. HPLC is considered as one of the gold
59	standard for HbA1c analysis due to its accuracy in simultaneous quantification of
60	both HbA1c and Hb concentrations in whole blood to obtain the HbA1c
61	percentage [20, 21]. Nevertheless, these methods have limitations such as
62	complexity, availability, requirement for experienced and skilled personnel, cost,
63	time consuming, and interference from endogenous and exogenous compounds
64	[22, 23]. Point-of-care testing (POCT) of HbA1c appears to be a user-friendly
65	approach to timely and accurately diagnose DM compared to the standard
66	method. A number of biosensor-based POCTs for the quantitative determination
67	of HbA1c concentration in blood have been developed. Biosensor for HbA1c
68	detection offers potential analytical and testing devise design with regard to test

69	sensitivity, cost, simplicity, robustness and miniaturization [24, 25]. Among these,
70	electrochemical biosensors respond to biological samples rapidly and are suitable
71	for miniaturization ability, rapid and on-site detection, portability, and flexibility
72	[26].
73	In the present study, the applicability of the newly developed nanoparticle-
74	based electrochemical biosensor - multiwalled nanotubes corporated with gold
75	nanoparticles (POCT-HbA1c ^{MWCNTs/AuNPs}) as a routine POCT for detection of
76	HbA1c for the diagnosis purpose was investigated [27]. Green synthesis (green
77	chemistry), instead of the conventional approach using toxic chemicals, was
78	applied for the preparation of the gold nanoparticles. The performance of the test
79	was validated in blood samples obtained from patients with confirmed DM and
80	non-DM subjects.
81	
82	Materials and Methods
83	Electrochemical-Biosensor Microchip
84	The development of electrochemical-biosensor microchip based on multi-

walled carbon nanotubes/gold-nanoparticles (MWCNTs/AuNPs) modified screenprinted carbon electrode (SPCE) for measurement of HbA1c, and total Hb in
blood samples has previously been described in detail [27]. In brief, sensor based
on the gold nanoparticles (AuNPs) was synthesized from passion fruit (*Passiflora edulis*) peel extracts. The prepared AuNPs (2 ml) were mixed with multiwalled
carbon nanotubes (MWCNTs, 5 mg) in various ratios (1:1, 1:2, and 2:1) to form
MWCNTs/AuNPs composites. The prepared MWCNTs/AuNPs were

92	characterized for morphology (Transmission electron microscope: TEM), particle
93	size (Dynamic light scattering), crystallinity (X-ray diffraction), functional groups
94	(Fourier transform infrared spectra), UV-absorbance (UV-vis-spectrophotometry),
95	and elemental composition (Energy-dispersive X-ray spectrometry). The
96	nanoparticles are spherical with a diameter of approximately 18 nm, with the
97	crystal structure of face-centred cubic and maximum UV-vis peak at 550 nm. The
98	small AuNPs and the intermeshing of the MWCNTs improve conductivity of
99	composite material. This property, in conjunction with the carbon nanotubes
100	result in good stability and good supports on the fabrication of an electrochemical
101	sensing system. The MWCNTs/AuNPs composite was drop-casted on the SPCE
102	for MWCNTs/AuNPs/SPCE working electrode preparation. The working
103	electrode was air-dried to remove all solvents. The electrochemical response of
104	modified electrodes to WMCNTs:AuNPs (1:1, 1:2, 2:1) was measured using
105	cyclic voltammetry (CV) by PalmSens4 Potentiostat/Galvanostat/Impedance
106	Analyzer (PalmSens, Netherlands). The electrochemical cells consisted of a
107	MWCNTs/AuNPs electrode (working electrode), Ag/AgCl (reference electrode),
108	and platinum electrode (counter electrode). The format of POCT-
109	HbA1c ^{MWCNTs/AuNPs} is shown in Fig 1.
110	
111	Fig 1. The format of POCT-HbA1c MWCNTs/AuNPs (Adapted from ref.27).
112	
113	The responses of MWCNTs/AuNPs/SPCE electrodes to different
114	concentrations of total Hb and HbA1c were investigated by square wave

voltammetry (SWV) over the concentration range 5-13 g/dl and 0.186-2.044 g/dl,

- 116 respectively to construct the calibration curves. The percentage of HbA1c was
- 117 calculated according to DCCT/NGSP: HbA1c (%) = (HbA1c/Hb)x91.5+2.15 [28,
- 118 **29**].
- 119
- 120 Patients
- 121 The study was approved by the Ethics Committee, Faculty of Medicine,
- 122 Thammasat University (approval number 157/2564, project number MTU-EC-00-
- 123 4-062/64). The study was conducted at Thammasat Chalermprakiet Hospital and
- 124 Thammasat University Center of Excellence in Pharmacology and Molecular
- 125 Biology of Malaria and Cholangiocarcinoma, following the guidelines outlined in
- 126 the Declaration of Helsinki. Written informed consents were obtained from all
- 127 subjects before study participation. A minimum of 138 study subjects (69 each for
- 128 DM and non-DM subjects) were recruited for the study. The sample size was
- 129 estimated using the formula:

130
$$n = \frac{\left[\left(Z_{\frac{\alpha}{2}}\right)^2 \times (1-P)\right]}{d^2}$$

Where n = sample size, Z = 95% confidence interval (1.96), and d
(%error) = 5%. P is the sensitivity (0.96) and specificity (0.90) of the POCTs
reported in previous studies [30].
Inclusion criteria for the DM group were (i) clinically and laboratoryconfirmed DM of all types and stages (ii) males or females (non-pregnant or nonlactating), (iii) aged between 20 and 70 years, and (iv) willing to participate in the

137	study. Exclusion criteria were those with (i) significant abnormality on physical
138	examination, (ii) presence of significant diseases that may affect the study, (iii)
139	abnormal coagulation or concurrent use of anticoagulant/antiplatelet agents, or
140	(vi) participation in any other study within the past 90 days.
141	Inclusion criteria for the non-DM group were (i) males or females (non-
142	pregnant or non-lactating), (ii) aged between 20 and 70 years, (iii) body mass
143	index (BMI) between 18 and 25 kg/m ² , (iv) non-smokers and non-alcoholic
144	drinkers, and (vii) willing to participate in the study. Exclusion criteria were those
145	with (i) significant abnormality on physical examination, (ii) history of or having
146	hepatitis B or hepatitis C virus or HIV infection, (v) abnormal coagulation or
147	concurrent use of anticoagulant/antiplatelet agents, or (vi) participation in any
148	other clinical study within the past 90 days.
149	Blood samples were collected from all volunteers after overnight fasting
150	(8-10 hours). Venous blood samples (3 ml each) were collected in EDTA tubes
151	and transferred to the Bangkok Pathology-Laboratory Co. Ltd. for determination
152	of HbA1c (Automated HbA1c, BioRad D-10 HPLC), total Hb, red blood cell
153	count (RBC), hematocrit, mean cell volume (MCV), mean cell hemoglobin
154	(MCH), mean cell hemoglobin concentration (MCHC), red blood cell distribution
155	width (RDW), platelet count, white blood cell count (WBC). The cut-off value of
156	DM diagnosis is HbA1c \geq 6.5%.
157	

158 Measurement of HbA1c and Total Hb Concentrations in Blood Samples

159	Twenty microliters (20 μ l) of finger-prick blood were mixed with 50 μ l of
160	hemolyzing reagent (consisting of 0.9% tetradecylammonium bromide 26.5
161	mmol/l), and an aliquot of cell suspension (5 μ l) was dropped onto a
162	MWCNTs/AuNPs/SPCE electrode. Electrochemical response was measured
163	using SWV by PalmSens4 Potentiostat/Galvanostat/Impedance Analyzer
164	(PalmSens, Netherlands).
165	
166	Evaluation of the performance of POCT-HbA1c MWCNTs/AuNPs
167	<i>POCT-HbA1c^{MWCNTs/AuNPs} performance:</i> The performance (sensitivity,
168	specificity, positive and negative predictive values, and accuracy) of the POCT-
169	HbA1c ^{MWCNTs/AuNPs} was evaluated by comparing the measured HbA1c values
170	with those measured by the reference laboratory method using the standard cut-
171	off HbA1c level of $\geq 6.5\%$ [9]. The test performances were estimated as follows:
172	Sensitivity (%) = $TP/(TP+FN)$
173	Specificity (%) = TN/(TN+FP)
174	Positive predictive value (%) = $TN/(TN+FN)$
175	Negative predictive value (%) = $TP/(TP+FP)$
176	Accuracy (%) = $(TP+TN)/(TP+TN+FP+FN)$
177	False-positive (%) = Number of misdiagnosed DM cases by POCT/Total
178	number of negative cases by reference method
179	False-negative (%) = Number of misdiagnosed non-DM cases by
180	POCT/Total number of positive cases by reference method

181	Where $TP = True positive$, $TN = True negative$, $FP = False positive$, $FN =$
182	False negative.
183	Test agreement analysis: The 95% confidence interval and the mean
184	relative error were estimated by the Bland-Altman plot and PasinggeBablok
185	regression analysis (MedCalc Software, Mariakerke, Belgium) to determine the
186	consistency of the HbA1c values measured by POCT-HbA1c ^{$MWCNTs/AuNPs$} and
187	those measured by the reference laboratory method.
188	
189	Statistics
190	The statistical analysis was performed using SPSS 17.0 software.
191	Quantitative variables are summarized as median (range) and mean (SD) values
192	for variables with non-normal and normal distribution, respectively. Deviation of
193	the mean HbA1c value measured by POCT test from the value measured by the
194	reference laboratory method was expressed as %DMV (% deviation from mean
195	value). The correlation between the concentrations of the two quantitative
196	variables was determined using Spearman's or Pearson's correlation test for
197	variables with non-normal or normal distribution, respectively. Statistical
198	significance was set at α =0.05.
199	
200	Results
201	Electrochemical Detection of Total Hb
202	The responses of MWCNTs/AuNPs/SPCE electrodes (SWV) to different
203	total Hb concentrations are shown in Fig 2. The MWCNTs/AuNPs/SPCE

204	electrodes generated an oxidation peak at -0.3 V. The intensity of the peak current
205	was proportional to the concentration of total Hb over the concentration range of
206	5-13.8 g/dl. The position of the oxidation peak remained unchanged with the
207	increased concentrations of total Hb. The limit of detection was 5 g/dl. The
208	equation for linear regression was: IP (μA) = 1.228C+21.287, with a correlation
209	coefficient (r) of 0.9004 (Fig 2).
210	
211	Fig 2. (A) SWV voltammograms for detection of total Hb with
212	MWCNTs/AuNPs/SPCE electrodes, and (B) Plot of current vs total Hb
213	concentration (Adapted from ref.27).
214	
215	Electrochemical Detection of HbA1c
216	For SWV, the peak current was increased with increased Hb1Ac
217	concentrations (0.186-2.044 g/dl) (Fig 3). The relationship between the current
218	and Hb1Ac concentration was linear: $I_P(\mu A) = 8.6488C+11.122$, r=0.9645). The
219	limit of detection was 0.186 g/dl. The specificity test for HbA1c was carried out
220	against Hb, BSA and glucose under identical experimental conditions.
221	
222	Fig 3. (A) SWV voltammograms for detection of HbA1c with

- 223 MWCNTs/AuNPs/SPCE electrodes, and (B) Plot of current vs HbA1c
- concentration (Adapted from ref.27).
- 225
- 226 Analysis of the Performance of POCT-HbA1c^{MWCNTs/AuNPs}

227	Analysis of the performance of the POCT-HbA1c compared with the
228	reference laboratory method was performed in 108 DM and 98 non-DM subjects.
229	Median (range) HbA1c concentrations measured by POCT-HbA1c ^{MWCNTs/AuNPs} in
230	DM patients were 0.64 (0.36-0.93) and 0.48 (0.22-0.64) g/dl, respectively
231	[corresponding to 7.19 (5.18-11.89) and 6.03 (4.10-6.40) % of total Hb,
232	respectively]. The corresponding HbA1c concentrations measured by the
233	reference method were 0.70 (0.39-1.78) and 0.45 (0.25-0.66) g/dl, respectively
234	[corresponding to 7.10 (4.80-14.00) and 5.30 (4.30-6.40) % of total Hb,
235	respectively). Median (range) total Hb concentrations measured by POCT-
236	HbA1c ^{MWCNTs/AuNPs} in DM patients were 12.65 (10.26-14.71) and 11.46 (9.65-
237	12.58) g/dl, respectively. The corresponding total Hb concentrations measured by
238	the reference method were 13.10 (10.50-15.50) and 13.00 (8.80-15.20) g/dl,
239	respectively.
240	POCT-HbA1c ^{MWCNTs/AuNPs} performance: To evaluate the clinical
241	applicability of the POCT-HbA1c ^{MWCNTs/AuNPs} , the HbA1c values measured by the
242	POCT-HbA1c ^{MWCNTs/AuNPs} were compared with that measured by the reference
243	laboratory method using the cut-off value of 6.5% (Table 1). The sensitivity and
244	specificity of the POCT-HbA1c were 100.00% (82/82) and 90.32% (112/124),
245	respectively. The probability of DM diagnosis in a subject with HbA1c \geq 6.5
246	(positive predictive value) was 87.23% (82/94). The probability of misdiagnosis
247	in a subject with HbA1c <6.5 (negative predictive value) was 100.00% (112/112).
248	The accuracy of the POCT-HbA1c ^{MWCNTs/AuNPs} expressed as a proportion of true

- 249 positives and true negatives (correctly classified by POCT-HbA1c^{MWCNTs/AuNPs}) in
- all subjects was 94.18%, with %DMV of 0.25%.
- 251
- 252 **Table 1.** Analysis of HbA1c levels using POCT-HbA1c ^{MWCNTs/AuNPs} based on the
- 253 6.5% cut-off value. Data are presented as the number of subjects (n=206).

HbA1c measured by	HbA1c measured by reference laboratory method (%)	
POCT (%)	$HbA1c \ge 6.5$	HbA1c < 6.5
HbA1c \geq 6.5	82	12
HbA1c < 6.5	0	112
Total	82	124

254

255 *Test agreement analysis:* Bland-Altman plot analysis of the HbA1c

analyzed by POCT-HbA1c^{MWCNTs/AuNPs} and the reference methods was performed,

and results showed that only 12 subjects had values outside the 95% CI

258 (confidence interval) of the range of agreement limit (-1.65614 to 1.36814),

suggesting that 94.18% of the value measured by POCT-HbA1c^{MWCNTs/AuNPs} was

in agreement with that measured by the standard method (Fig 4).

261

262 Fig 4. Bland-Altman plot analysis for accuracy of HbA1c measured by POCT-

263 HbA1c compared with the reference method in 206 blood samples collected from

- 264 DM and non-DM subjects.
- 265
- 266 Clinical Application of POCT-HbA1c^{MWCNTs/AuNPs}

267	Clinical application of the POCT-HbA1c ^{MWCNTs/AuNPs} was evaluated in
268	108 DM and 98 non-DM subjects. The demographic and laboratory data of the
269	DM and non-DM subjects are summarized in Table 2. Excellent linear correlation
270	(p < 0.0001, Y = 2.25 + 0.69 * X, r = +0.874) was found between the HbA1c values
271	measured by POCT-HbA1c and the reference laboratory method (Fig 5). There
272	was a moderate linear correlation between FPG and HbA1c levels measured by
273	the standard methods in DM and non-DM subjects (r= 0.552 , $p < 0.0001$).
074	

274

Table 2. Demographic, glucose level and hematological data of DM and non-DM

subjects. Data are presented as number (%) or mean (SD) and median (range) values.

Parameter		DM	Non-DM
Gender (n, %)	Male	37 (33.90%)	14 (14.03%)
	Female	71 (65.10%)	84 (85.70%)
Age (yr)	Mean (SD)	59.8 (12.7)	32.6 (9.1)
	Median (range)	60.9 (20.5-86.3)	31.0 (15.9-57.8)
Body weight (kg)	Mean (SD)	70.5 (15.7)	59.0 (11.8)
	Median (range)	68.0 (37.3-130.0)	56.0 (38.5-88.0)
BMI	Mean (SD)	27.13 (5.28)	22.76 (4.19)
	Median (range)	25.95 (16.56-	21.67 (15.13-
	Wedian (range)	48.93)	34.38)
Glucose (mg/dl)	Mean (SD)	179.3 (79.8)	108.0 (22.2)
	Median (range)	156.0 (68.0-	101.0 (79.0-
		442.0)	222.0)

Parameter		DM	Non-DM
Hemoglobin (g/dl)	Mean (SD)	13.0 (1.2)	12.9 (1.2)
	Median (range)	13.1 (10.5-15.5)	13.0 (9.8-15.2)
Hematocrit (%)	Mean (SD)	40.0 (3.8)	40.2 (3.9)
	Median (range)	39.9 (31.6-48.5)	40.0 (32.2-48.8)
Platelet (x10 ³ /µl)	Mean (SD)	264.80 (71.18)	290.92 (59.30)
	Median (range)	2604.00 (69.00-	282.00 (152.00-
		507.00)	450.00)
RBC (x10 ⁶ /µl)	Mean (SD)	4.69 (0.59)	4.77 (0.59)
	Median (range)	4.58 (3.76-6.84)	4.73 (3.78-6.77)
HbA1c (g/dl)	Mean (SD)	0.77 (0.27)	0.45 (0.08)
	Median (range)	0.70 (0.39-1.78)	0.45 (0.25-0.66)
HbA1c (%)	Mean (SD)	7.57 (1.80)	5.33 (0.42)
	Median (range)	7.10 (4.80-14.00)	5.30 (4.30-6.40)
MCV (fl)	Mean (SD)	85.94 (7.87)	85.01 (9.07)
	Median (range)	87.30 (60.4-98.9)	87.90 (63.00-
			97.10)
MCH (pg)	Mean (SD)	28.60 (2.80)	27.34 (3.22)
	Median (range)	28.60 (20.10-	27.90 (19.40-
		32.60)	32.40)
MCHC (g/dl)	Mean (SD)	.3263.0) 87(32.12 (1.03)
	Median (range)	.328 0(30.10-	32.20 (27.90-
		35.10)	33.60)

Parameter		DM	Non-DM
RDW (%)	Mean (SD)	12.93 (1.02)	13.06 (1.35)
	Median (range)	12.70 (11.00-	12.80 (11.00-
		16.60)	18.00)
WBC (x10 ³ /µl)	Mean (SD)	7.43 (2.04)	6.52 (1.48)
	Median (range)	7.36 (3.76-15.76)	6.55 (2.49-10.58)
Neutrophil %)	Mean (SD)	59.65 (8.56)	54.31 (9.12)
	Madian (ranga)	59.10 (34.70-	54.50 (23.80-
	Median (range)	41.80)	73.30)
Lymphocyte (%)	Mean (SD)	32.55 (8.17)	38.18 (8.68)
	Madian (ranga)	32.60 (17.10-	36.50 (16.60-
	Median (range)	56.70)	68.70)
Monocyte (%)	Mean (SD)	3.60 (1.71)	2.85 (1.09)
	Median (range)	2.90 (1.00-9.00)	2.50 (1.00-6.10)
Eosinophil (%)	Mean (SD)	3.56 (2.64)	3.96 (1.92)
	Median (range)	2.90 (0.50-19.70)	3.60 (1.00-10.00)
Basophil (%)	Mean (SD)	0.57 (0.29)	0.71 (0.35)
	Median (range)	0.50 (0.0-1.6)	0.60 (0-2)

277

Fig 5. Correlation between HbA1C concentrations measured by POCT-HbA1c

279 MWCNTs/AuNPs and the reference laboratory methods in 206 subjects (108 DM and

280 98 non-DM subjects). (p < 0.0001, r=+0.874).

282	Correlation	analysis of	the HbA1c va	lues measured	by POCT-
		-			-

- 283 HbA1c^{MWCNTs/AuNPs} and hematological parameters (Hb, Hct, MCV, MCHC, and
- RDW) was performed to determine hematological factors that could influence the
- 285 measurement of HbA1c by POCT-HbA1c^{MWCNTs/AuNPs}. Only two parameters were
- found to be significantly correlated with the measured HbA1c by POCT-
- 287 HbA1c^{MWCNTs/AuNPs}. Total Hb concentration (measured by POCT-
- HbA1c^{MWCNTs/AuNPs} and reference method) was weakly (r=+0.310) but
- significantly (p < 0.0001) correlated with the HbA1c measured by POCT-
- HbA1c^{MWCNTs/AuNPs}. On the other hand, a negative correlation (r=-0.214, p=0.002)
- 291 was found between MCHC and HbA1c values measured by POCT-
- HbA1c^{MWCNTs/AuNPs}.
- 293

294 **Discussion**

295 The glycosylated Hb is formed *via* a spontaneous non-enzymatic reaction

between glucose and the *N*-terminal residues of beta-globin chain in Hb to

297 generate unstable Schiff base intermediates. Then, the intermediate goes through

- an irreversible Amadori rearrangement to synthesize the stable ketoamine [31].
- 299 The accomplishment of quantitative HbA1c provides in-depth and accurate
- 300 detection for clinical application. A number of HbA1c POCT devices are
- 301 currently available in clinical settings, of which the detection method is either
- 302 affinity-based separation or immunoassay techniques. Biosensor with
- 303 electrochemical detection has also been developed as POCT for HbA1c. Each has
- 304 some limitations, *e.g.*, test complications requiring multi-steps of sample

305	preparation [32], and the requirement of large blood sample volume [33].
306	Furthermore, most are subject to interferences from Hb variants (HbC, HbE, HbS,
307	and others) and modified Hb (carbamylated and acetylated Hb, or labile HbA1c)
308	[34]. The analysis showed that most of the HbA1c POCT devices have a mean
309	negativity bias compared to laboratory assays, as well as a high variability among
310	the bias value within devices. Recently, gold nanoflowers modified
311	electrochemical biosensor based on 4-mercaptophenylboronic acid was developed
312	for the quantitative determination of HbA1c [35]. In this study, we investigated
313	the clinical applicability of the POCT-HbA1c MWCNTs/AuNPs previously developed
314	in our laboratory [27] for the accurate diagnosis of DM. The test was sensitive
315	and specific for the determination of HbA1c in the blood (from both venipuncture
316	and finger-prick), exploiting the catalytic property of HbA1c for the reduction
317	reaction of H_2O_2 to produce the electrochemical signal. The biosensor was
318	prepared from gold nanoparticles (AuNPs) in multiwalled carbon nanotubes
319	(MWCNTs) as MWCNTs/AuNPs composites. The obvious advantage of the test
320	is the use of green synthesis (green chemistry) for the synthesis of AuNPs from
321	passion fruit peel instead of toxic chemicals. In addition, it is the label-free
322	method that assures rapid detection. AuNPs were electrochemically deposited
323	onto the SPCE. The starch composition in the passion fruit peel with different
324	amylose pectins acts as a reducing agent in the electrochemical reaction [36]. This
325	label-free method could assure rapid detection with as small a volume as 20 μl of
326	blood. Only a single step pre-treatment of blood samples is required to remove
327	plasma interference, followed by lysis of the RBC. The POCT-

328	HbA1c ^{MWCNTs/AuNPs} provides simultaneous determination of both HbA1c and total
329	Hb concentrations in a single reaction. This feature not only reduces the testing
330	time but also reduces the errors from the use of different reactions.
331	To demonstrate the clinical applicability of the developed POCT-
332	HbA1c ^{MWCNTs/AuNPs} electrochemical biosensor, the concentrations of HbA1c in
333	blood samples from DM and non-DM subjects measured by the POCT-
334	$HbA1c^{MWCNT_s/AuNP_s}$ and the reference laboratory methods were compared. Results
335	show high sensitivity (100%), specificity (90.32%), accuracy (94.18%), and
336	excellent application prospects in clinical practice. The probability of a diagnosis
337	of DM in subjects with HbA1c level $\geq 6.5\%$ (positive predictive value) was
338	87.23%, while the probability of misdiagnosis of DM in subjects with HbA1c
339	level <6.5% (negative predictive value) was 100.00%. The agreement of the
340	values measured by both methods was excellent ($r=+0.874$). The Bland-Altman
341	plot suggested that 94.18% of the value measured by POCT-HbA1c ^{MWCNTs/AuNPs}
342	was in agreement with that measured by the standard method. The HbA1c level
343	was correlated with FPG as previously reported [11]. The measurement of HbA1c
344	as a percentage of total Hb relies on the accuracy of measurement of both HbA1c
345	and total Hb concentrations. A weak linear correlation was found between total
346	Hb concentration (measured by standard and POCT-HbA1c ^{MWCNTs/AuNPs} methods)
347	and HbA1c concentration measured by POCT-HbA1c ^{MWCNTs/AuNPs} (r=+0.32). This
348	suggests little influence of the total Hb on HbA1c concentration measured by
349	POCT-HbA1 $c^{MWCNT_s/AuNP_s}$, and the POCT-HbA1 $c^{MWCNT_s/AuNP_s}$ could have wide
350	clinical applicability in patients regardless of the Hb concentration. The influence

351	of total Hb concentration on HbA1c determination has been reported in patients
352	with hemoglobinopathies such as thalassemia. The hematocrit varies among
353	individuals, which leads to differences in total Hb. The low level of hematocrit
354	could be due to the following reasons: the amounts of RBC and Hb in RBC are
355	not enough to completely fill the surface of the sensor, and/or HbA1c does not
356	reflect an actual ratio. On the other hand, the MCHC value, which relates to the
357	volume of RBC, affected the HbAc1 level measured by POCT-
358	HbA1c ^{MWCNTs/AuNPs} in a reverse direction; the higher the MCHC concentration,
359	the lower the HbA1c concentration measured by POCT-HbA1c ^{MWCNTs/AuNPs} (r=-
360	0.214, $p=0.002$). Falsely high HbA1c level has been reported with conditions that
361	prolong the life-span of RBC (e.g., iron deficiency anemia), severe
362	hypertriglyceremia (>1,750 mg/dl), severe albuminemia (>20 mg/dl), alcohol
363	intake and administration of some drugs (e.g., salicylate, opioids) [37]. On the
364	other hand, falsely low HbA1c level has been reported in conditions that shorten
365	the life-span of RBCs and splenomegaly, pregnancy, and administration of some
366	drugs (e.g., ribavirin, cephalosporin, and levofloxacin).
367	In conclusion, the results of the study indicate satisfactory assay
368	performance and applicability of the POCT-HbA1c ^{MWCNTs/AuNPs} based on gold
369	nanoparticles modified screen-printed carbon electrode for diagnosis of DM using
370	the cut-off criteria of HbA1c \geq 6.5%. The POCT-HbA1c ^{MWCNTs/AuNPs} is an
371	accurate and easy-to-use tool that provides the test results on the spot and become
372	an effective tool in establishing the DM diagnosis, especially in vulnerable or
373	hard-to-reach populations. It does not require fasting before measurement, and the

374	sample can be stored at 4 C° for at least two weeks in the case when measurement
375	cannot be performed immediately [38, 39]. The user-friendly format in
376	smartphone application (MyA1c) is being developed for clinical use in routine
377	diagnosis of DM. The implication of using POCT-HbA1c ^{MWCNTs/AuNPs} in medical
378	treatment decision-making to control DM patients and patient outcomes needs to
379	be further evaluated.
380	
381	Acknowledgments
382	We thank Dr. Panida Kongjam (Clinical Coordination, WHO collaborating
383	Center, Thammasat University) for statistical analysis and Miss Akkaracha
384	Hanwattanakul (Faculty of Science and Technology, Thammasat University) for
385	data collection.
386	
387	Author contributions
388	Conceptualization: Kesara Na-Bangchang, Kanyarat Boonprasert, Chiravoot
389	Pechyen
390	Data Curation: Kesara Na-Bangchang, Kanyarat Boonprasert, Thipaporn
391	Tharavanij
392	Formal Analysis: Kesara Na-Bangchang, Kanyarat Boonprasert
393	Funding Acquisition: Kesara Na-Bangchang, Kanyarat Boonprasert
394	Investigation: Kanyarat Boonprasert, Khanittha Ponsanti
395	Methodology: Kesara Na-Bangchang, Kanyarat Boonprasert, Chiravoot Pechyen,
396	Benchamaporn Tangnorawich

397	Project Administration: Kesara Na-Bangchang, Kanyarat Boonprasert
398	Resources: Kesara Na-Bangchang, Chiravoot Pechyen, Thipaporn Tharavanij
399	Software: Kanyarat Boonprasert, Chiravoot Pechyen, Khanittha Ponsanti,
400	Benchamaporn Tangnorawich
401	Supervision: Kesara Na-Bangchang, Thipaporn Tharavanij, Vithoon Viyanant,
402	Benchamaporn Tangnorawich
403	Validation: Kesara Na-Bangchang, Kanyarat Boonprasert, Vithoon Viyanant
404	Visualization: Kanyarat Boonprasert, Chiravoot Pechyen, Khanittha Ponsanti
405	Writing – Original Draft Preparation: Kesara Na-Bangchang, Kanyarat
406	Boonprasert,
407	Writing – Review & Editing: Kanyarat Boonprasert, Thipaporn Tharavanij,
408	Chiravoot Pechyen, Khanittha Ponsanti, Benchamaporn Tangnorawich,
409	Vithoon Viyanant, Kesara Na-Bangchang
410	
411	Declaration of Conflict Interest
412	The authors declare that they have no known competing financial interests

413 or personal relationships or affiliations that could have appeared to influence the414 work reported in this paper.

415

416 Funding

417 The study was supported by the National Research Council of Thailand

418 (Genetic markers and Point-of-care test for Healthy Aging: 169/2563), and a

419 Ph.D. scholarship from Thammasat University.

420

421 **References**

- 422 1. American Diabetes Association. Diagnosis and classification of diabetes
- 423 mellitus. Diabetes Care. 2009;32(Suppl 1):S62–7.
- 424 2. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata
- 425 L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of
- 426 diabetes for 2015 and 2040. Diab Res Clin Prac. 2017;128:40–50.
- 427 3. Mousavi SM, Hashemi SA, Gholami A, Mazraedoost S, Chiang W-H,
- 428 Arjmand O, et al. Precise blood glucose sensing by nitrogen-doped graphene
- 429 quantum dots for tight control of diabetes. J Sensor. 2021;2021:14.
- 430 4. Gupta S, Jain U, Chauhan N. Laboratory diagnosis of HbA1c: a review. J
- 431 Nanomed Res. 2017;5(4):00120.
- 432 5. Vashist P, Singh S, Gupta N, Saxena R. Role of early screening for diabetic
- 433 retinopathy in patients with diabetes mellitus: an overview. Indian J Comm
- 434 Med. 2011;36(4):247–52.
- 435 6. Adepoyibi T, Weigl B, Greb H, Neogi T, McGuire H. New screening
- 436 technologies for type 2 diabetes mellitus appropriate for use in tuberculosis
- 437 patients. Publ Hlth Act. 2013;3(Suppl 1):S10–7.
- 438 7. Lenters-Westra E, Schindhelm RK, Bilo HJ, Slingerland RJ. Haemoglobin
- 439 A1c: historical overview and current concepts. Diab Res Clin Pract.
- 440 2013;99(2):75–84.

441	8.	International Expert Committee. International Expert Committee report on the
442		role of the A1C assay in the diagnosis of diabetes. Diabetes Care.
443		2009;32(7):1327–34.
444	9.	American Diabetes Association. Standards of medical care in diabetes-2018
445		Abridged for primary care providers. Clin Diabetes. 2018;36(1):14-37.
446	10	. World Health Organization. Use of glycated haemoglobin (HbA1c) in the
447		diagnosis of diabetes mellitus: abbreviated report of a WHO consultation.
448		Geneva: World Health Organization; 2011.
449	11	. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and
450		serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia.
451		Clin Exp Med. 2007;7(1):24–9.
452	12	. Chandalia HB, Krishnaswamy PR. Glycated Haemoglobin. Curr Sci.
453		2002;83(12):1522–32.
454	13	. Thienpont LM, Van Uytfanghe K, De Leenheer AP. Reference measurement
455		systems in clinical chemistry. Clin Chim Acta. 2002;323(1-2):73-87.
456	14	. Pundir CS, Chawla S. Determination of glycated hemoglobin with special
457		emphasis on biosensing methods. Anal Biochem. 2014;444:47-56.
458	15	. Stöllner D, Stöcklein W, Scheller F, Warsinke A. Membrane-immobilized
459		haptoglobin as affinity matrix for a hemoglobin-A1c immunosensor. Anal
460		Chim Acta. 2002;470(2):111–9.
461	16	. Liu L, Hood S, Wang Y, Bezverkov R, Dou C, Datta A, et al. Direct
462		enzymatic assay for %HbA1c in human whole blood samples. Clin Biochem.

463 2008;41(7–8):576–83.

464	17. Parker KM, England JD, Costa JD, Hess RL, Goldstein DE. Improved
465	colorimetric assay for glycosylated hemoglobin. Clin Chem. 1981;27(5):669-
466	72.
467	18. Chopra A, Tuteja S, Sachdeva N, Bhasin KK, Bhalla V, Suri CR. CdTe
468	nanobioprobe based optoelectrochemical immunodetection of diabetic marker
469	HbA1c. Biosens Bioelectron. 2013;44:132–5.
470	19. Chen HH, Wu CH, Tsai ML, Huang YJ, Chen SH. Detection of total and A1c-
471	glycosylated hemoglobin in human whole blood using sandwich
472	immunoassays on polydimethylsiloxane-based antibody microarrays. Anal
473	Chem. 2012;84(20):8635–41.
474	20. Kaiser P, Akerboom T, Molnar P, Reinauer H. Modified HPLC-electrospray
475	ionization/mass spectrometry method for HbA1c based on IFCC reference
476	measurement procedure. Clin Chem. 2008;54(6):1018-22.
477	21. Kaur J, Jiang C, Liu G. Different strategies for detection of HbA1c
478	emphasizing on biosensors and point-of-care analyzers. Biosens Bioelectron.
479	2019;123:85–100.
480	22. Cork J, Jones RM, Sawyer J. Low cost, disposable biosensors allow detection
481	of antibodies with results equivalent to ELISA in 15 min. J Immunol Methods.
482	2013;387(1-2):140-6.
483	23. Parkash O, Shueb RH. Diagnosis of dengue infection using conventional and
484	biosensor based techniques. Viruses. 2015;7(10):5410-27.
485	24. Mehrabi F, Vafaei A, Ghaedi M, Ghaedi AM, Alipanahpour Dil E, Asfaram
486	A. Ultrasound assisted extraction of Maxilon Red GRL dye from water

487	samples using cobalt ferrite nanoparticles loaded on activated carbon as
488	sorbent: Optimization and modeling. Ultrason Sonochem. 2017;38:672-80.
489	25. Alipanahpour Dil E, Ghaedi M, Asfaram A, Mehrabi F, Bazrafshan AA.
490	Optimization of process parameters for determination of trace Hazardous dyes
491	from industrial wastewaters based on nanostructures materials under
492	ultrasound energy. Ultrason Sonochem. 2018;40:238-48.
493	26. Salek-Maghsoudi Vakhshiteh AF, Torabi R, Hassani S, Ganjali MR, Norouzi
494	P, Hosseini M, et al. Recent advances in biosensor technology in assessment
495	of early diabetes biomarkers. Biosens Bioelectron. 2018;99:122-35.
496	27. Ponsanti K, Ngernyang N, Tangnorawich B, Na-Bangchang K, Boonprasert
497	K, Tasanarong A, et al. A novel electrochemical-biosensor microchip based
498	on MWCNTs/AuNPs for detection of glycated hemoglobin (HbA1c) in
499	diabetes patients. J Electrochem Soc. 2022;169(3):11.
500	28. Diabetes Control in Clinical Practice. The effect of intensive treatment of
501	diabetes on the development and progression of longterm complications in
502	insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
503	29. NGSP. IFCC Standardization of HbA1c; 2010 [cited 21 October 2021]. In:
504	National Glycohemoglobin Standardization Program [Internet]. Available
505	from: <u>http://www.ngsp.org/ifcc.asp</u> .
506	30. Wang Y, Peng W, Tang J, Dong L, Gu C, Zhang X, et al. Verification of a
507	novel point-of-care HbA1c device in real world clinical practice by
508	comparison to three high performance liquid chromatography instruments.
509	Biochem Med (Zagreb). 2018;28(2):020705.

- 510 31. Bunn HF, Haney DN, Gabbay KH, Gallop PM. Further identification of the
- 511 nature and linkage of the carbohydrate in hemoglobin A1c. Biochem Biophys
- 512 Res Commun. 1975;67(1):103–9.
- 513 32. Kim DM, Shim YB. Disposable amperometric glycated hemoglobin sensor
- for the finger prick blood test. Anal Chem. 2013;85(13):6536–43.
- 515 33. Chopra A, Rawat S, Bhalla V, Suri CR. Point-of-Care amperometric testing of
- 516 diabetic marker (HbA1c) using specific electroactive antibodies. Electroanal.
- 517 2014;26(3):469–72.
- 518 34. Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, et al.
- 519 Approved IFCC reference method for the measurement of HbA1c in human
- 520 blood. Clin Chem Lab Med. 2002;40(1):78–89.
- 521 35. Wang X, Su J, Zeng D, Liu G, Liu L, Xu Y, et al. Gold nano-flowers (Au
- 522 NFs) modified screen-printed carbon electrode electrochemical biosensor for
- 523 label-free and quantitative detection of glycated hemoglobin. Talanta.
- 524 2019;201:119–25.
- 525 36. Ponsanti K, Tangnorawich B, Ngernyuang N, Pechyen C. A flower shape-
- 526 green synthesis and characterization of silver nanoparticles (AgNPs) with
- 527 different starch as a reducing agent. J Mater Res Tech. 2020;9(5):11003–12.
- 37. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be
 misleading. J Gen Intern Med. 2014;29(2):388–94.
- 530 38. Little RR, Rohlfing CL, Tennill AL, Connolly S, Hanson S. Effects of sample
- 531 storage conditions on glycated hemoglobin measurement: evaluation of five

- 532 different high performance liquid chromatography methods. Diabetes Technol
- 533 Ther. 2007;9(1):36–42.
- 534 39. Ezenwaka CE, Seales D, Surujlal R, Mathura RP. Glycated haemoglobin A1c
- 535 measurement in stored whole blood sample is reliable for clinical use. West
- 536 Indian Med J. 2009;58(1):17–20.
- 537





Figure







